Xeris Pharmaceuticals | Brutto Fortjeneste På Salg



Gross Profit On Sales Endring Dato
Adcock Ingram Holdings ZAR 1.61B 802K 2024-06
Celltrion KRW 463.41B 95.59B 2024-09
Cspc Pharmaceutical CNY 4.33B 828.42M 2024-09
Ecofibre AUD 2.08M 4.33M 2024-06
Eli Lilly USD 11.13B 1.86B 2024-12
Kangmei Pharma CNY 176.17M 370.88K 2024-09
Knight Therapeutics CAD 45.02M 2.32M 2024-09
Laboratorios Farma EUR 110.32M 24.65M 2024-06
Malin Corporation EUR 3.8M 2.6M 2020-12
Medical Developments International AUD 13.36M 2.36M 2024-06
Organigram Holdings CAD 1.05M 67.34M 2024-12
Pacira USD 147.37M 17.66M 2024-12
Perrigo USD 385.9M 18.5M 2024-12
Pharma Mar EUR 47.05M 3.4M 2024-12
Qiagen NV USD 349.8M 19.17M 2024-12
Sartorius EUR 345.1M 43.2M 2024-09
Sino Biopharmaceutical CNY 6.51B 2.67B 2024-06
Supernus Pharmaceuticals USD 156.96M 1.14M 2024-12
Tilray USD 61.22M 1.51M 2024-11
Zz Pientze Pharmaceu 1.29B 268M 2024-09



Xeris Pharmaceuticals Brutto Fortjeneste På Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.